Appili Therapeutics (APLI) Stock Overview

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

APLI Stock Information

Symbol

APLI

Address

#21-1344 Summer StreetHalifax, NS B3H 0A8Canada

Founded

Trading hours

Website

https://www.appilitherapeutics.com

Country

🇨🇦 Canada

Phone Number

902-442-4655

Appili Therapeutics (APLI) Price Chart

Appili Therapeutics Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.025942259941444615	N/A
Market Cap	$2.95M	N/A
Shares Outstanding	113.73M	70.43%
Employees	8.00	N/A
Shareholder Equity	-7.40M	126.17%

Valuation	2023	Change
P/E Ratio	-0.32	N/A
P/S Ratio	11.91	N/A
P/B Ratio	-0.40	N/A

Growth	2023	Change
Return on Equity	0.9262	N/A

Earnings	2023	Change
Revenue	$247.69K	N/A
Earnings	-$6.85M	N/A
EPS	-0.08	N/A
Earnings Yield	-3.08	N/A
Operating Margin	-23.27	N/A
Net income margin	-27.66	N/A

Financial Strength	2023	Change
Total Assets	$2.32M	N/A
Total Debt	$5.68M	N/A
Cash on Hand	$1.83M	N/A
Debt to Equity	-1.0551	-59.70%
Cash to Debt	0.3217	-75.97%
Current Ratio	$1.05	-15.24%